How many drugs treat Induce Anterograde Amnesia?

Drug Landscape tracks 4 marketed treatments for Induce Anterograde Amnesia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/induce-anterograde-amnesia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Induce Anterograde Amnesia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Induce Anterograde Amnesia (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Induce Anterograde Amnesia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
Valium	diazepam	Generic (originally Roche)	Benzodiazepine [EPC]	Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2	1963-11-15

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Roche) · 2 drugs in Induce Anterograde Amnesia
Generic (originally Wyeth/Pfizer) · 1 drug in Induce Anterograde Amnesia
Takeda Pharmaceutical Company Limited · 1 drug in Induce Anterograde Amnesia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Induce Anterograde Amnesia:

Cite this brief

Drug Landscape (2026). Induce Anterograde Amnesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/induce-anterograde-amnesia. Accessed 2026-06-11.

Induce Anterograde Amnesia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing